Russell Investments Group Ltd. reduced its stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 10.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 86,855 shares of the company’s stock after selling 10,590 shares during the quarter. Russell Investments Group Ltd. owned 0.33% of Oxford Immunotec Global worth $1,409,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Bank of Montreal Can purchased a new position in Oxford Immunotec Global in the 2nd quarter valued at about $132,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Oxford Immunotec Global in the 2nd quarter valued at about $333,000. Rhumbline Advisers boosted its position in Oxford Immunotec Global by 45.8% in the 2nd quarter. Rhumbline Advisers now owns 32,861 shares of the company’s stock valued at $424,000 after buying an additional 10,320 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new position in Oxford Immunotec Global in the 2nd quarter valued at about $140,000. Finally, Bellevue Group AG purchased a new position in Oxford Immunotec Global in the 2nd quarter valued at about $1,426,000. 90.94% of the stock is currently owned by institutional investors.
Shares of OXFD stock opened at $14.98 on Friday. Oxford Immunotec Global PLC has a one year low of $10.00 and a one year high of $19.19.
Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings results on Friday, November 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. The company had revenue of $16.10 million for the quarter, compared to the consensus estimate of $33.60 million. During the same period in the previous year, the business posted ($0.70) EPS. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. As a group, analysts expect that Oxford Immunotec Global PLC will post -1.09 earnings per share for the current year.
In other news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $15.50, for a total transaction of $46,500.00. Following the transaction, the director now owns 9,000 shares of the company’s stock, valued at $139,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter Wrighton-Smith sold 86,100 shares of the stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the transaction, the chief executive officer now directly owns 539,569 shares in the company, valued at approximately $9,938,860.98. The disclosure for this sale can be found here. Insiders have sold 109,100 shares of company stock worth $1,966,662 in the last ninety days. Corporate insiders own 6.61% of the company’s stock.
Several brokerages have recently commented on OXFD. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Oxford Immunotec Global in a research report on Sunday, November 11th. BidaskClub cut shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, ValuEngine cut shares of Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 1st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $16.67.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/12/08/oxford-immunotec-global-plc-oxfd-shares-sold-by-russell-investments-group-ltd.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Read More: How to read a candlestick chart
Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.